uploads/2019/01/Graph-7-8-1.png

Xeljanz: Pfizer’s Key Immunology Asset in Fiscal 2019

By

Updated

Immunology portfolio 

In fiscal 2018, Pfizer (PFE) reported I&I (inflammation and immunology) product sales of $4.08 billion—a rise of 3% YoY (year-over-year) on a reported and operational basis. Among the revenues, $1.56 billion was earned from the US market—a rise of 23% YoY. The international markets contributed the remaining $2.52 billion worth of revenues—a decline of 7% YoY on a reported and operational basis.

In the fourth quarter, Pfizer reported I&I product sales of $1.13 billion—a rise of 7% YoY on an operational basis and 2% on a reported basis. Among the revenues, $476 million was earned from the US market, while the remaining $652 million was earned from international markets.

Article continues below advertisement

Xeljanz’s growth trends

Pfizer’s key I&I asset, Xeljanz reported revenues of $1.77 billion in fiscal 2018—a rise of 323% YoY on an operational basis and 32% on a reported basis. Among the revenues, $1.39 billion was earned from the US market—a rise of 23% YoY. International markets contributed the remaining $380 million of the revenues—a rise of 79% YoY on a reported basis and 84% on an operational basis.

In the fourth quarter, Xeljanz reported sales of $553 million—a rise of 37% YoY on an operational basis and 35% on a reported basis. Among the revenues, $429 million was earned from the US market, while the remaining $124 million was earned from international markets.

According to Pfizer’s fourth-quarter earnings conference call, Pfizer reported a rise of 35% YoY in Xeljanz scripts in the fourth quarter due to the demand in rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis indications. Around 33% of Xeljanz’s volume growth in the United States was attributed to the drug’s recently approved indications for psoriatic arthritis and ulcerative colitis. According to Pfizer’s fourth-quarter earnings conference call, based on the company’s early data, Xeljanz seems to have outperformed Simponi in terms of the new patient share in the ulcerative colitis segment in the United States. Pfizer expects a total market opportunity of $10 billion for Xeljanz based on its three major approved indications.

Advertisement

More From Market Realist